Why Symbiotec Pharmalab IPO Is Chanakya’s Pick
Symbiotec Pharmalab IPO is emerging as an attractive opportunity for both listing gains and long-term investment. The current GMP of approximately Rs. 409 indicates a potential listing gain of nearly 41.40% over the upper issue price of Rs. 988, reflecting strong grey-market interest. However, GMP is unofficial and may change before listing.
The company has specialised capabilities in corticosteroid and steroidal hormone APIs, a backward-integrated manufacturing platform and approvals from major global regulators, including the US FDA and EU-GMP. These capabilities create significant entry barriers and strengthen its position in international pharmaceutical markets.
Although the post-issue P/E of 56.81 times appears expensive based on historical earnings, this valuation should also be viewed in the context of the company’s recent investment of approximately Rs. 800 crore in a new manufacturing plant. As capacity utilisation improves, the new facility could support faster revenue growth, operating leverage and higher profitability.
FY26 total income rose 15% to Rs. 872.26 crore, while PAT increased 14% to Rs. 109.90 crore. Borrowings also declined substantially.
Considering the strong GMP, specialised business, global approvals and expected benefits from the new plant, Symbiotec Pharmalab is Chanakya’s Pick for listing gains as well as long-term investment.
Chanakya Recommendation: 🟢 Apply